Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Project 4
- Development stage
- Preclinical
- Lead developer
- Chongqing Pharmaceutical
- Modality
- Small Molecules
01
Overview
Project 4 is a small molecule drug candidate currently in preclinical development by Chongqing Pharmaceutical (Chongqing Pharmaceutical Research Institute). It is designed to target cellular metabolism, a critical pathway that cancer cells exploit to support rapid proliferation and survival. By modulating these metabolic processes, Project 4 aims to selectively impair tumor cells while minimizing effects on healthy tissue. The specific molecular target within the metabolic pathway has not been disclosed. The drug is being investigated for its potential in treating various types of cancers and solid tumors.
- Other names
- Chongqing Pharmaceutical-Cell metabolism-small molecule-Cancer/Tumor
Beyond the preview
Go deeper on Project 4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Project 4.